**Abstract**

**Objective of the study**: Clozapine is one of well-known antipsychotics which causes hematologic adverse effects, specifically neutropenia and agranulocytosis (1--3% of patients). We found a rare case of thrombocytosis and anemia after the re-administration of clozapine.

**Methods used:** We reviewed the documents about clozapine induced hematologic adverse-effects, esp. anemia and thrombocytosis. And we summarized the case of anemia and thrombocytosis after re-start of clozapine by the result of hematologic work-up and clinical responses of it.

**Summary of results:** Reports about blood dyscrasias like anemia and thrombocytosis after clozapine treatment has been extremely rare. In some cases, re-challenge of clozapine could lead to hematopoietic abnormality related to thrombocytopenia or thrombocytosis, which is may be a result of an immune reaction. The details of hematologic finding are shown in the graph.

**Conclusions reaches**: This case report suggest that clinician should monitor platelet count after the re-treatment of clozapine.
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